Cefepime
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01413 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 22 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | polyclonal hyperviscosity syndrome | KG + DL |
| 2 | hyperamylasemia | KG + DL |
| 3 | congenital analbuminemia | KG + DL |
| 4 | blood group incompatibility | KG + DL |
| 5 | premalignant hematological system disease | KG + DL |
| 6 | monoclonal gammopathy | KG + DL |
| 7 | hematological disease associated with an acquired peripheral neuropathy | KG + DL |
| 8 | septicemic plague | KG + DL |
| 9 | congenital hematological disorder | KG + DL |
| 10 | infectious otitis media | KG + DL |
| 11 | suppurative otitis media | KG + DL |
| 12 | chronic otitis media | KG + DL |
| 13 | otosalpingitis | KG + DL |
| 14 | middle ear disease | KG + DL |
| 15 | allergic otitis media | KG + DL |
| 16 | middle ear cholesterol granuloma | KG + DL |
| 17 | non-suppurative otitis media | KG + DL |
| 18 | hematopoietic and lymphoid system neoplasm | KG + DL |
| 19 | bubonic plague | KG + DL |
| 20 | pneumonia | KG + DL |
| 21 | bacterial arthritis | KG + DL |
| 22 | Peptostreptococcus infectious disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.